BioAge Shares Collapse After Novo Nordisk’s ZEUS Phase 3 Misses Cardiovascular Endpoints
BioAge Labs stock plunged roughly 60% following Novo Nordisk’s announcement that its Phase 3 ZEUS study of ziltivekimab did not reduce the risk of major adverse cardiovascular events versus placebo in more than 6,300 patients. The outcome, which produced a hazard ratio of 0.99, hit investor confidence in inflammation-targeting cardiovascular therap…